Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Year: 2012
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: The University of Texas MD Anderson Cancer Center, Princess Margaret Cancer Centre, Hôpital Saint-Louis, Recherche clinique appliquée à l'hématologie, Nizam's Institute of Medical Sciences, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, Hospices Civils de Lyon
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: omacetaxine mepesuccinate, chronic myeloid leukemia, T315I mutation, tyrosine kinase inhibitor resistance, protein synthesis inhibitors, subcutaneous administration, complete hematologic response, major cytogenetic response, progression-free survival, hematologic toxicity, chronic phase CML
Open Access status: green
OpenAlex ID: W2031892240
